---
document_datetime: 2025-12-29 14:32:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/quadramet.html
document_name: quadramet.html
version: success
processing_time: 0.1261465
conversion_datetime: 2025-12-31 03:30:39.293047
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Quadramet

[RSS](/en/individual-human-medicine.xml/66973)

##### Authorised

This medicine is authorised for use in the European Union

samarium [153Sm] lexidronam pentasodium Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80772)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Quadramet?

Quadramet is a solution for injection containing the active substance samarium [ 153 Sm] lexidronam pentasodium.

## What is Quadramet used for?

Quadramet is used to relieve bone pain in patients with multiple painful osteoblastic skeletal metastases (when cancer has spread to the bones). Osteoblastic metastases are a type of bone metastasis where new bone tissue grows rapidly. Quadramet is only used in bone metastases that can take up a type of chemical called bisphosphonates, as this means that the metastases will also take up Quadramet. Before receiving Quadramet patients should have a bone scan using bisphosphonates radiolabelled with technetium-99m [ 99m Tc] as markers, to check that their metastases are of the type that Quadramet can be used for.

The medicine can only be obtained with a prescription.

## How is Quadramet used?

Quadramet should only be handled and given by someone who is authorised to use radioactive medicines and after full oncological (cancer) evaluation. The dose of Quadramet is calculated based on the patient's body weight to provide a specific dose of radioactivity (37 mega becquerels per kilogram body weight). The medicine is given by slow intravenous injection (into a vein) over one minute. Patients who respond to Quadramet generally have relief of their pain within one week of treatment. The pain relief may last for up to four months.

## How does Quadramet work?

Quadramet is a radiopharmaceutical product. Its active substance is samarium [ 153 Sm] lexidronam pentasodium. It is a complex (a type of chemical) made up of a radioactive element, samarium-153 ( 153 Sm), bound to another chemical called 'ethylene diamine tetra methylene phosphonic acid' (EDTMP).

When Quadramet is injected into a patient, the complex is distributed around the body via the bloodstream. Because EDMTP has a high affinity for bone tissue, it accumulates in the bone, especially in areas of rapid bone growth such as osteoblastic metastases. As a result, the radiation brought by the samarium-153 can act locally and help to relieve the bone pain.

## How has Quadramet been studied?

Quadramet has been studied in 373 patients in three main studies. In two of these, the effectiveness of Quadramet was compared with that of placebo (a dummy treatment). The main measure of effectiveness was the reduction of pain. This was measured using various means, such as visual or descriptive scales, analgesic (painkiller) use, and assessment by the doctor.

## What benefit has Quadramet shown during the studies?

Quadramet was effective in providing pain relief from osteoblastic bone metastases, and, where it was compared with placebo, more effective than placebo. In one of the studies, which involved patients with bone metastases from prostate cancer, the patients' use of opioid analgesics (such as morphine) was also reduced following treatment with Quadramet.

## What is the risk associated with Quadramet?

The main side effects of Quadramet are a reduction in red and white blood cell and platelet counts. The following side effects have also been reported: asthenia (weakness), nausea (feeling sick), vomiting, diarrhoea, peripheral oedema (fluid retention), headaches, hypotension (low blood pressure), dizziness, myasthenia (muscle weakness), confusion and sweating. For the full list of all side effects reported with Quadramet, see the package leaflet.

Quadramet should not be used in people who may be hypersensitive (allergic) to EDTMP or to phosphonates (similar chemical compounds). It should not be used in pregnant women or in patients who have had chemotherapy or hemi-body external radiotherapy in the previous six weeks. Quadramet should not be used at the same time as any chemotherapy that affects the bone marrow or at the same time as other bisphosphonate medicines if these can interact with the way Quadramet fixes to bone metastases.

## Why has Quadramet been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Quadramet's benefits are greater than its risks for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases. The Committee recommended that Quadramet be given marketing authorisation.

## Other information about Quadramet

The European Commission granted a marketing authorisation valid throughout the European Union for Quadramet to CIS bio international on 5 February 1998. The marketing authorisation was renewed on 5 February 2003 and on 5 February 2008.

Quadramet : EPAR - Summary for the public

English (EN) (43.43 KB - PDF)

**First published:** 31/03/2008

**Last updated:** 31/03/2008

[View](/en/documents/overview/quadramet-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-168)

български (BG) (165.95 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/bg/documents/overview/quadramet-epar-summary-public_bg.pdf)

español (ES) (44.76 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/es/documents/overview/quadramet-epar-summary-public_es.pdf)

čeština (CS) (161.24 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/cs/documents/overview/quadramet-epar-summary-public_cs.pdf)

dansk (DA) (44.4 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/da/documents/overview/quadramet-epar-summary-public_da.pdf)

Deutsch (DE) (45.43 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/de/documents/overview/quadramet-epar-summary-public_de.pdf)

eesti keel (ET) (44.02 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/et/documents/overview/quadramet-epar-summary-public_et.pdf)

ελληνικά (EL) (164.22 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/el/documents/overview/quadramet-epar-summary-public_el.pdf)

français (FR) (43.47 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/fr/documents/overview/quadramet-epar-summary-public_fr.pdf)

italiano (IT) (44.57 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/it/documents/overview/quadramet-epar-summary-public_it.pdf)

latviešu valoda (LV) (161.8 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/lv/documents/overview/quadramet-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (156.52 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/lt/documents/overview/quadramet-epar-summary-public_lt.pdf)

magyar (HU) (153.55 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/hu/documents/overview/quadramet-epar-summary-public_hu.pdf)

Malti (MT) (164.43 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/mt/documents/overview/quadramet-epar-summary-public_mt.pdf)

Nederlands (NL) (44.94 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/nl/documents/overview/quadramet-epar-summary-public_nl.pdf)

polski (PL) (167.28 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/pl/documents/overview/quadramet-epar-summary-public_pl.pdf)

português (PT) (45.4 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/pt/documents/overview/quadramet-epar-summary-public_pt.pdf)

română (RO) (150.77 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/ro/documents/overview/quadramet-epar-summary-public_ro.pdf)

slovenčina (SK) (158.42 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/sk/documents/overview/quadramet-epar-summary-public_sk.pdf)

slovenščina (SL) (147.33 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/sl/documents/overview/quadramet-epar-summary-public_sl.pdf)

Suomi (FI) (44.48 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/fi/documents/overview/quadramet-epar-summary-public_fi.pdf)

svenska (SV) (44.41 KB - PDF)

**First published:**

31/03/2008

**Last updated:**

31/03/2008

[View](/sv/documents/overview/quadramet-epar-summary-public_sv.pdf)

## Product information

Quadramet : EPAR - Product Information

English (EN) (383.96 KB - PDF)

**First published:** 14/08/2008

**Last updated:** 31/10/2025

[View](/en/documents/product-information/quadramet-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-435)

български (BG) (457.18 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/bg/documents/product-information/quadramet-epar-product-information_bg.pdf)

español (ES) (323.09 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/es/documents/product-information/quadramet-epar-product-information_es.pdf)

čeština (CS) (443.45 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/cs/documents/product-information/quadramet-epar-product-information_cs.pdf)

dansk (DA) (376.37 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/da/documents/product-information/quadramet-epar-product-information_da.pdf)

Deutsch (DE) (409.25 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/de/documents/product-information/quadramet-epar-product-information_de.pdf)

eesti keel (ET) (399.54 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/et/documents/product-information/quadramet-epar-product-information_et.pdf)

ελληνικά (EL) (468.25 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/el/documents/product-information/quadramet-epar-product-information_el.pdf)

français (FR) (398.55 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/fr/documents/product-information/quadramet-epar-product-information_fr.pdf)

hrvatski (HR) (473.07 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/hr/documents/product-information/quadramet-epar-product-information_hr.pdf)

íslenska (IS) (457.16 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/is/documents/product-information/quadramet-epar-product-information_is.pdf)

italiano (IT) (391.24 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/it/documents/product-information/quadramet-epar-product-information_it.pdf)

latviešu valoda (LV) (426.62 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/lv/documents/product-information/quadramet-epar-product-information_lv.pdf)

lietuvių kalba (LT) (441.26 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/lt/documents/product-information/quadramet-epar-product-information_lt.pdf)

magyar (HU) (538.33 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/hu/documents/product-information/quadramet-epar-product-information_hu.pdf)

Malti (MT) (518.32 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/mt/documents/product-information/quadramet-epar-product-information_mt.pdf)

Nederlands (NL) (343.18 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/nl/documents/product-information/quadramet-epar-product-information_nl.pdf)

norsk (NO) (406.12 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/no/documents/product-information/quadramet-epar-product-information_no.pdf)

polski (PL) (420.37 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/pl/documents/product-information/quadramet-epar-product-information_pl.pdf)

português (PT) (390.02 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/pt/documents/product-information/quadramet-epar-product-information_pt.pdf)

română (RO) (444.51 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/ro/documents/product-information/quadramet-epar-product-information_ro.pdf)

slovenčina (SK) (446.44 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/sk/documents/product-information/quadramet-epar-product-information_sk.pdf)

slovenščina (SL) (421.43 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/sl/documents/product-information/quadramet-epar-product-information_sl.pdf)

Suomi (FI) (452.36 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/fi/documents/product-information/quadramet-epar-product-information_fi.pdf)

svenska (SV) (368.67 KB - PDF)

**First published:**

14/08/2008

**Last updated:**

29/10/2025

[View](/sv/documents/product-information/quadramet-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246157 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Quadramet : EPAR - All Authorised presentations

English (EN) (61.81 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-637)

български (BG) (81.48 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/bg/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_bg.pdf)

español (ES) (60.45 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/es/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_es.pdf)

čeština (CS) (82.18 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/cs/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (63.77 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/da/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (65.92 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/de/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (60.29 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/et/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (77.34 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/el/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_el.pdf)

français (FR) (60.65 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fr/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (34.44 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hr/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.26 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/is/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_is.pdf)

italiano (IT) (57.97 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/it/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (84.03 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lv/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (81.49 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lt/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (82.38 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hu/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (82.29 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/mt/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (69.08 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/nl/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.33 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/no/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_no.pdf)

polski (PL) (86.97 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pl/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_pl.pdf)

português (PT) (61.05 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pt/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_pt.pdf)

română (RO) (78.75 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/ro/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (82.62 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sk/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (72.73 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sl/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.77 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fi/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (61.43 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sv/documents/all-authorised-presentations/quadramet-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Quadramet Active substance samarium (153Sm) lexidronam pentasodium International non-proprietary name (INN) or common name samarium [153Sm] lexidronam pentasodium Therapeutic area (MeSH)

- Pain
- Cancer

Anatomical therapeutic chemical (ATC) code V10BX02

### Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

### Therapeutic indication

Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [ 99m Tc]-labelled biphosphonates on bone scan.

The presence of osteoblastic metastases which take up technetium [ 99m Tc]-labelled biphosphonates should be confirmed prior to therapy.

## Authorisation details

EMA product number EMEA/H/C/000150 Marketing authorisation holder

CIS bio international

Route Nationale 306, Saclay

Marketing authorisation issued 04/02/1998 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Quadramet : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (125.33 KB - PDF)

**First published:** 31/10/2025

[View](/en/documents/procedural-steps-after/quadramet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Quadramet : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (167.37 KB - PDF)

**First published:** 14/08/2008

**Last updated:** 06/11/2025

[View](/en/documents/procedural-steps-after/quadramet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Quadramet : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (84.22 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/quadramet-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Quadramet : EPAR - Procedural steps taken before authorisation

English (EN) (85.8 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/quadramet-epar-procedural-steps-taken-authorisation_en.pdf)

Quadramet : EPAR - Scientific Discussion

English (EN) (177.71 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/quadramet-epar-scientific-discussion_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Quadramet : EPAR - Product information - tracked changes

English (EN) (113.59 KB - DOCX)

**First published:** 06/11/2025

[View](/en/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-695)

български (BG) (116.53 KB - DOCX)

**First published:**

06/11/2025

[View](/bg/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_bg.docx)

español (ES) (113.75 KB - DOCX)

**First published:**

06/11/2025

[View](/es/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_es.docx)

čeština (CS) (272 KB - DOC)

**First published:**

06/11/2025

[View](/cs/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (114.76 KB - DOCX)

**First published:**

06/11/2025

[View](/da/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (125.31 KB - DOCX)

**First published:**

06/11/2025

[View](/de/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (107.81 KB - DOCX)

**First published:**

06/11/2025

[View](/et/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (135.31 KB - DOCX)

**First published:**

06/11/2025

[View](/el/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_el.docx)

français (FR) (100.31 KB - DOCX)

**First published:**

06/11/2025

[View](/fr/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (122.66 KB - DOCX)

**First published:**

06/11/2025

[View](/hr/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (96.14 KB - DOCX)

**First published:**

06/11/2025

[View](/is/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_is.docx)

italiano (IT) (116.13 KB - DOCX)

**First published:**

06/11/2025

[View](/it/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (98.79 KB - DOCX)

**First published:**

06/11/2025

[View](/lv/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (122.12 KB - DOCX)

**First published:**

06/11/2025

[View](/lt/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (137.08 KB - DOCX)

**First published:**

06/11/2025

[View](/hu/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (119.33 KB - DOCX)

**First published:**

06/11/2025

[View](/mt/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (115.11 KB - DOCX)

**First published:**

06/11/2025

[View](/nl/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (138.21 KB - DOCX)

**First published:**

06/11/2025

[View](/no/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_no.docx)

polski (PL) (115.29 KB - DOCX)

**First published:**

06/11/2025

[View](/pl/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_pl.docx)

português (PT) (114.75 KB - DOCX)

**First published:**

06/11/2025

[View](/pt/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_pt.docx)

română (RO) (117.19 KB - DOCX)

**First published:**

06/11/2025

[View](/ro/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (132.32 KB - DOCX)

**First published:**

06/11/2025

[View](/sk/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (114.52 KB - DOCX)

**First published:**

06/11/2025

[View](/sl/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (122.28 KB - DOCX)

**First published:**

06/11/2025

[View](/fi/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (78.56 KB - DOCX)

**First published:**

06/11/2025

[View](/sv/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/11/2025

## Share this page

[Back to top](#main-content)